179 related articles for article (PubMed ID: 35773251)
1. Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.
Miller PG; Sathappa M; Moroco JA; Jiang W; Qian Y; Iqbal S; Guo Q; Giacomelli AO; Shaw S; Vernier C; Bajrami B; Yang X; Raffier C; Sperling AS; Gibson CJ; Kahn J; Jin C; Ranaghan M; Caliman A; Brousseau M; Fischer ES; Lintner R; Piccioni F; Campbell AJ; Root DE; Garvie CW; Ebert BL
Nat Commun; 2022 Jun; 13(1):3778. PubMed ID: 35773251
[TBL] [Abstract][Full Text] [Related]
2. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
3. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Kojima K; Maeda A; Yoshimura M; Nishida Y; Kimura S
Oncotarget; 2016 Oct; 7(43):69625-69637. PubMed ID: 27626308
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
5. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
6. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
7.
Kahn JD; Miller PG; Silver AJ; Sellar RS; Bhatt S; Gibson C; McConkey M; Adams D; Mar B; Mertins P; Fereshetian S; Krug K; Zhu H; Letai A; Carr SA; Doench J; Jaiswal S; Ebert BL
Blood; 2018 Sep; 132(11):1095-1105. PubMed ID: 29954749
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
9. The role of PPM1D in cancer and advances in studies of its inhibitors.
Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Kamada R; Kudoh F; Yoshimura F; Tanino K; Sakaguchi K
J Biochem; 2017 Oct; 162(4):303-308. PubMed ID: 28486685
[TBL] [Abstract][Full Text] [Related]
12. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
13. PPM1D regulates p21 expression via dephoshporylation at serine 123.
Cao R; Zhang J; Zhang M; Chen X
Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K
Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770
[TBL] [Abstract][Full Text] [Related]
15. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
16. Protein phosphatase, Mg
Husby S; Hjermind Justesen E; Grønbæk K
Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
[TBL] [Abstract][Full Text] [Related]
17. De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
Jansen S; Geuer S; Pfundt R; Brough R; Ghongane P; Herkert JC; Marco EJ; Willemsen MH; Kleefstra T; Hannibal M; Shieh JT; Lynch SA; Flinter F; FitzPatrick DR; Gardham A; Bernhard B; Ragge N; Newbury-Ecob R; Bernier R; Kvarnung M; Magnusson EA; Wessels MW; van Slegtenhorst MA; Monaghan KG; de Vries P; Veltman JA; ; Lord CJ; Vissers LE; de Vries BB
Am J Hum Genet; 2017 Apr; 100(4):650-658. PubMed ID: 28343630
[TBL] [Abstract][Full Text] [Related]
18. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Gilmartin AG; Faitg TH; Richter M; Groy A; Seefeld MA; Darcy MG; Peng X; Federowicz K; Yang J; Zhang SY; Minthorn E; Jaworski JP; Schaber M; Martens S; McNulty DE; Sinnamon RH; Zhang H; Kirkpatrick RB; Nevins N; Cui G; Pietrak B; Diaz E; Jones A; Brandt M; Schwartz B; Heerding DA; Kumar R
Nat Chem Biol; 2014 Mar; 10(3):181-7. PubMed ID: 24390428
[TBL] [Abstract][Full Text] [Related]
19. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Kim B; Won D; Lee ST; Choi JR
PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
[TBL] [Abstract][Full Text] [Related]
20. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
